Abstract
11107 Background: In India LABC remains a common presentation of breast cancer (BC). Pathological complete response (pCR) achievement is crucial for increasing survival in LABC. Taxanes and anthracyclines are amongst agents with highest activity in BC. We retrospectively evaluated clinical and pathological responses in LABC patients (pts) treated with T and AC based chemotherapy. Methods: 32 LABC pts with clinical stage IIB, IIIA, IIIB, IIIC who had received T & AC based NAC between October 2002 and October 2006 were evaluated. Patients received doxorubicin 60mg/m2 (21 pts) or epirubicin 75 mg/m2 (11 pts) and docetaxel 75 mg/m2 (all pts) 3 weekly for 3–4 cycles followed by surgery. Most pts received same chemotherapy as adjuvant and also radiation therapy and hormonal treatment depending upon ER, PgR status. Results: Baseline characteristics of 32 pts: median age 50 years (range 26–65); all female; performance status 0–1; clinical stage IIB (3 pts), IIIA (9 pts), IIIB (16 pts), IIIC (4 pts); node positive (25 pts), hormone receptor positive (17 pts), unknown (1 pt); 29 pts received 3 cycles of NAC, 3 pts received 4 cycles of NAC. Growth factor was used in all patients. 31 pts underwent MRM; 5 pts had clinically complete response (16%), 22 pts had partial response (69%), 4 pts had stable disease (12%), 1 pt had progressive disease (3%); pathological complete response was seen in 4 pts (12 %). There were 2 events of febrile neutropenia; grade 3 or 4 neutropenia was seen in 26 pts (81%). There was no significant thrombocytopenia, cardiovascular event and hypersensitivity reaction. Conclusions: Our analysis indicates that T and AC based chemotherapy is well tolerated and effective in Indian pts with LABC with response rates similar to international studies. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
